Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis
- 1 September 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 11 (9) , 735-738
- https://doi.org/10.1097/00003246-198309000-00013
Abstract
Gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, has an anticoagulant activity in the absence of antithrombin-III. We investigated FOY therapy for the treatment of disseminated intravascular coagulation (DIC) associated with sepsis in 15 patients (group F), and compared it with heparin therapy in 8 patients (group H). Successful treatment was observed in 13 patients in group F and in 4 patients in group H. The efficacy of the therapy in both groups was not significantly different. However, in patients whose antithrombin-III values were less than 20 mg/dl at the initiation of the therapy, FOY therapy was successful in 6 of 7 patients, whereas heparin therapy was not at all successful in 4 patients (pKeywords
This publication has 0 references indexed in Scilit: